Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 18/20 | 0.48 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13950725 | 0.85 | RIOK2 (0.49) | NR3C2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL29078768 | 0.80 | NR3C2 (0.50) | NR3C2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL5070476 | 0.78 | RECQL (0.52) | NR3C2RECQL | |
| SCHEMBL5913167 | 0.77 | NR3C2 (0.53) | NR3C2RECQLKMT2A | |
| SCHEMBL501285 | 0.76 | L3MBTL1 (0.52) | NR3C2RECQL | |
| SCHEMBL29507273 | 0.76 | L3MBTL1 (0.52) | NR3C2RECQL | |
| SCHEMBL2780621 | 0.75 | SMN1; SMN2 (0.61) | RECQLALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL29601179 | 0.75 | SMN1; SMN2 (0.61) | RECQLALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL2779409 | 0.75 | RIOK2 (0.43) | NR3C2ALDH1A1KMT2ASMN1; SMN2 | |
| SCHEMBL28712383 | 0.75 | PHGDH (0.48) | NR3C2ALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7709475-B2 | 5-[2-(cyclohexyloxy)-6-methyl-4-pyrimidinyl]-2-[5-(4-methyl-1-piperazinyl)methyl-2-pyrazinyl]amino-1,3-thiazole; anticarcinogenic agent; G1 phase in cell cycle; great selectivity | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-05-04 | — | — | US | disclosed |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | BANYU PHARMACEUTICAL CO., LTD (JP) | 2008-04-03 | — | — | US | disclosed |
| EP-1218376-B1 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2005-11-09 | — | — | EP | disclosed |
| US-6586424-B2 | Anticancer agents; anticholesterol agents | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-6586423-B2 | 2-(Pyridin-2-ylamino)-thiazole-5-carbonitrile derivatives; angiogenesis inhibitors; antitumor and anticarcinogenic agents; atherosclerosis, macular degeneration, diabetic retinopathy | MERCK & CO., INC. | 2003-07-01 | — | — | US | disclosed |
| US-20030064996-A1 | Tyrosine kinase inhibitors | MERCK SHARP & DOHME CORP. | 2003-04-03 | — | — | US | disclosed |
| CN-1390215-A | Tyrosine kinase inhibitors | MERCK & CO INC (US) | 2003-01-08 | — | — | CN | disclosed |
| EP-1218376-A4 | TYROSINE KINASE INHIBITORS | MERCK & CO INC (US) | 2002-11-20 | — | — | EP | disclosed |
| US-20020147203-A1 | Tyrosine kinase inhibitors | MERCK & CO., INC. | 2002-10-10 | — | — | US | disclosed |
| EP-1218376-A1 | TYROSINE KINASE INHIBITORS | Merck & Co., Inc. (US) | 2002-07-03 | — | — | EP | disclosed |
| WO-2001017995-A1 | TYROSINE KINASE INHIBITORS | MERCK & CO., INC. (US) | 2001-03-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020147203-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NR3C2 2235/4885RECQL 4074/4885ALDH1A1 3104/4885 |
| US-20080081811-A1 | Selective Inhibitors Against Cdk4 and Cdk6 Having Aminothiazole Skeleton | CDK4, CDK6, CDK3 | NR3C2 360/4885RECQL 2305/4885ALDH1A1 3347/4885 |
| US-20030064996-A1 | Tyrosine kinase inhibitors | ERBB2, TYRO3, TIE1 | NR3C2 2235/4885RECQL 4074/4885ALDH1A1 3104/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.